CH₃CH₃
official

Memantine: general

by ch3ch3 · 8h ago · 0 comments

Memantine is a prescription medicine. Its US label says it is “indicated for the treatment of moderate to severe dementia of the Alzheimer’s type”.⁠[1] It is also sold as a powder and taken off-label as a nootropic, and sometimes as a dissociative; the experiences section collects those reports. This page is a summary of what the label and the research say. It is not medical advice and it gives no amounts.

How it acts

The label describes memantine as a “low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist”.⁠[1] In plain terms, it partly blocks one of the brain's main glutamate receptors, the same receptor that ketamine, PCP and dextromethorphan block more strongly. Even in its approved use the label is modest about what that achieves: “There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease”.⁠[1]

Does it work as a nootropic?

There is human data on this, but very little. In a placebo-controlled study of “Sixteen male healthy volunteers”, a single dose did not sharpen anyone: “There were no significant effects of memantine on mood, attention or immediate and delayed verbal and visuospatial memory”.⁠[2] It did measurably slow one kind of learning, appearing to “delay the acquisition of classical eyeblink conditioning”.⁠[2] That is one small, single-dose study, so it cannot settle the question either way, but it points away from enhancement rather than towards it. A 2022 review of so-called smart drugs in healthy people reached a similar conclusion for the class as a whole: “their efficacy in healthy individuals is uncertain and any reported improvement temporary”.⁠[3]

Side effects

In the clinical trials behind the label, the most common side effects were “dizziness, headache, confusion and constipation”.⁠[1] Those trials were in older people with dementia, so they say little about how a younger, healthy person will react. The label also notes that memantine “has not been systematically evaluated in patients with a seizure disorder”.⁠[1]

Interactions

Two warnings on the label matter most to people taking memantine on their own.

  • Other NMDA blockers. The label says combining memantine with “amantadine, ketamine, and dextromethorphan has not been systematically evaluated and such use should be approached with caution”.⁠[1] Dextromethorphan is in many cough medicines, and ketamine is used both medically and recreationally, so this is not a rare combination.
  • Anything that makes urine alkaline. Memantine leaves the body through the kidneys, and alkaline urine slows that down, which “may lead to an accumulation of the drug with a possible increase in adverse effects”.⁠[1] The label names diet and drugs such as “carbonic anhydrase inhibitors, sodium bicarbonate” as causes.⁠[1] Kidney disease has the same effect, which is why the label lowers the amount for people with poor kidney function.⁠[1]

Overdose

The label lists the signs seen after memantine overdose, alone or with other drugs or alcohol: “agitation, asthenia, bradycardia, confusion, coma, dizziness, ECG changes, increased blood pressure, lethargy, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness”.⁠[1] It adds that “Fatal outcome has been very rarely reported with memantine”, though in those cases the link to memantine was unclear.⁠[1] A 2024 case report describes an older man brought to hospital with “abrupt onset of altered mental status and auditory hallucinations” after an overdose, and its authors flag raised blood pressure as “hypertension, which is easy to overlook as a medication side effect”.⁠[4] Anyone who may have taken too much should contact a poison control centre or emergency services.

What is not known

The label does not discuss abuse or dependence. Our PubMed search on 2026-11-21 returned 243 records on memantine and abuse, misuse, overdose or intoxication; most were trials of memantine as a treatment for addiction or pain.⁠[5] Unprescribed use is real enough to be counted: a 2026 survey of pharmacy students defined non-medical use of cognitive enhancers as “unprescribed use of donepezil, memantine, racetams, methylphenidate, or modafinil”.⁠[6] But we found no study of what that use does to the people taking it.⁠[5] That is the limit of what our search found, not evidence that non-medical use is safe. Nothing in the record tells us what months of off-label use does to a healthy person, and a powder bought from a vendor has none of the checks a pharmacy tablet does.

References

  1. MEMANTINE tablet, prescribing information (Dr. Reddy's, ANDA090048), DailyMed — US National Library of Medicine, DailyMed
  2. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans (Schugens et al., Neuroscience Letters, 1997) — PubMed (US National Library of Medicine)
  3. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals (Schifano et al., Drugs, 2022) — PubMed (US National Library of Medicine)
  4. Case report: a unique presentation of memantine overdose causing echolalia and hypertension (Durrani and Ahmed, BMC Geriatrics, 2024) — PubMed (US National Library of Medicine)
  5. PubMed search for memantine AND (abuse OR misuse OR recreational OR overdose OR intoxication) (run 2026-11-21: 243 records, most of them trials of memantine as a treatment for addiction or pain; a handful of overdose case reports; one survey counting unprescribed use; no study of its effects) — PubMed (US National Library of Medicine)
  6. Non-Medical Use of Cognitive Enhancers Among Lebanese Pharmacy Students: A National Cross-Sectional Survey (Substance Use and Misuse, 2026) — PubMed (US National Library of Medicine)
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something